Toxicology Studies for FDA GRAS Dossiers: Data Requirements and Test Standard Selection

General Principles of the Toxicology Report

• Comprehensiveness and Relevance:

  The report should provide a comprehensive review of all available toxicological data relevant to the notified substance, including toxicity information on the substance itself, its structural analogs, and its major metabolites. The data presented must be directly relevant to the intended conditions of use, the anticipated routes of exposure, and the target populations of concern.

• Scientific Rigor and Clear Justification:

  All cited studies should originate from reliable, peer-reviewed scientific literature or from experimental reports conducted in compliance with Good Laboratory Practice (GLP) standards. The data should be reproducible and interpretable. Toxicological data should not be merely listed; rather, they must be subjected to systematic analysis and critical evaluation, culminating in a clear, well-supported safety conclusion.

• Transparency and Traceability:

  All data sources, including literature citations, study report numbers, and any unpublished proprietary data, should be fully documented to ensure transparency and traceability of the information presented, allowing for independent verification by regulatory reviewers.

Interpretation and Application of Toxicological Data

• Determination of NOAEL/LOAEL:

  Based on the findings from toxicological studies, the No-Observed-Adverse-Effect Level (NOAEL) or the Lowest-Observed-Adverse-Effect Level (LOAEL) should be identified for the notified substance. The NOAEL derived from the most sensitive species and the most sensitive endpoint should be selected as the starting point for the safety assessment.

• Application of Safety Factors:

  The safety factor is a dimensionless ratio applied to the NOAEL to derive an Acceptable Daily Intake (ADI) or a safe level of intake. A safety factor of greater than 100 is generally considered acceptable. This 100-fold safety factor is a long-established empirical rule in toxicology, commonly known as the "uncertainty factor." It is typically derived from the product of two 10-fold factors:Additional factors (e.g., 10× each) may be applied for subchronic-to-chronic extrapolation or when using LOAEL instead of NOAEL. All safety factor selections must be scientifically justified.

• A 10-fold factor to account for interspecies differences (toxicokinetic and toxicodynamic variations between laboratory animals and humans).

• A 10-fold factor to account for interindividual differences (variations in sensitivity among different individuals within the human population).

• Comparison with Dietary Exposure Estimates:

  The derived safe intake level (e.g., ADI) should be compared with the estimated daily intake (EDI) derived from the dietary exposure assessment. If the EDI is substantially lower than the safe intake level, it can be concluded that the notified substance is safe under its intended conditions of use.

• Integrated Safety Conclusion:

  After integrating all available toxicological data, metabolic information, and exposure assessment results, a definitive safety conclusion should be drawn. The conclusion should be presented concisely and clearly, with explicit acknowledgment of any potential risks, data gaps, or areas that may require further attention or monitoring.

Should Key Toxicological Studies Conducted by Applicants Comply with GLP and OECD Standards?

Although the FDA GRAS framework is fundamentally based on the concept of "general recognition" rather than on a prescriptive regulatory mandate, it is important to note that the U.S. FDA does not impose a strict regulatory requirement for toxicological studies submitted in support of a GRAS notification to be conducted in full compliance with GLP or OECD test guidelines. In practice, however, adherence to these standards is highly recommended and has become all but essential for a successful submission.

GLP represents a rigorous quality system designed to ensure that non-clinical safety studies, including toxicological assays, are planned, performed, monitored, recorded, reported, and archived in a manner that guarantees reliability, integrity, and credibility. Data generated from studies that do not follow GLP standards may be subject to significant regulatory scrutiny due to a number of deficiencies, including: (i) lack of a detailed study protocol, leading to methodological concerns; (ii) inadequate documentation and retention of raw data, resulting in incomplete datasets; and (iii) absence of an independent quality assurance unit to oversee study conduct, undermining the credibility of the findings.

The OECD Guidelines for the Testing of Chemicals constitute a set of internationally recognized, standardized test methods for assessing the potential human health and environmental hazards of chemical substances. These guidelines represent the international gold standard for toxicological testing, with rigorous scientific validation of study design, animal numbers, observation endpoints, and data analysis methodologies. Studies conducted in accordance with OECD guidelines ensure scientific rigor and comparability of results, and the data generated are mutually acceptable among all OECD member countries, significantly reducing the cost and time associated with redundant testing.

Consequently, in order for toxicological data to withstand scrutiny by independent experts and the FDA, study reports submitted to demonstrate the safety of a substance typically include a GLP compliance statement. The FDA's official guidance document, the Redbook, explicitly states that toxicology reports submitted in support of food additive petitions and GRAS notifications should include a GLP compliance statement. Furthermore, to ensure the quality, credibility, and global applicability of the study data, the majority of applicants opt to conduct their toxicological studies in accordance with OECD guidelines.

Key Considerations for Preparing the Toxicology Section

• Clear and Concise Writing – Avoid Data Dumping: Use precise, technically accurate toxicological terminology and avoid vague or misleading expressions. The report should not merely be a compilation of toxicological studies; rather, the data should be logically organized and subjected to in-depth analysis and critical discussion.

• Data Quality and Timeliness – Prioritize Current, Relevant Data: Preference should be given to studies of high quality and reliability. Any studies with methodological limitations or inconsistencies should be identified, explained, and discussed in the context of the overall database. Prior to submission of the GRAS dossier, it is essential to ensure that all cited data are the most current, relevant, and representative of the substance and its intended conditions of use.

• Consideration of Sensitive Subpopulations: If the substance is likely to be consumed by sensitive populations, such as infants, young children, pregnant women, the elderly, or individuals with specific medical conditions, particular attention should be paid to the safety of these groups.

By adhering to the considerations outlined above, applicants can substantially enhance the quality and persuasiveness of the toxicology section of the GRAS dossier, thereby providing a robust scientific foundation for the conclusion that the substance is GRAS under its intended conditions of use.

How to Obtain GRAS Status?

In principle, any individual or organization may pursue a GRAS determination for a substance through either of the following two pathways:

• Self-Affirmed GRAS: This pathway involves convening a panel of qualified experts to evaluate the available safety data and conclude that the substance is GRAS under its intended conditions of use. The resulting GRAS determination is documented in a self-affirmed GRAS dossier, which is not submitted to the FDA and remains confidential to the notifier.

• FDA Notified GRAS: This pathway involves the preparation of a comprehensive GRAS dossier, which is then submitted to the FDA for formal review. The FDA evaluates the submission and issues a response, typically in the form of a "no questions letter" if the agency concurs with the GRAS determination.

It should be noted that an FDA GRAS notification generally incorporates the conclusions and expert opinions of the qualified expert panel that were originally developed for the self-affirmed GRAS determination.